Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 525-532

  Yerges Armstrong, L M ^a   Ellero Simatos, S ^b,c   Georgiades, A ^d   Zhu, H ^d   Lewis, J P ^a   Horenstein, R B ^a   Beitelshees, A L ^a   Dane, A ^b,c   Reijmers, T ^b,c   Hankemeier, T ^b,c   Fiehn, O ^e   Shuldiner, A R ^a   Kaddurah Daouk, R ^f  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

^c Netherlands Metabolomics Centre   (Netherlands)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE KINASE; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE PHOSPHATE; ARACHIDONIC ACID; ASPARTIC ACID; AZELAIC ACID; GUANOSINE; HYPOXANTHINE; INOSINE; LINOLEIC ACID; OLEIC ACID; PALMITOLEIC ACID; PURINE DERIVATIVE; RIBOSE; SALICYLIC ACID; SALICYLURIC ACID; SHIKIMIC ACID; XANTHINE;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RESISTANCE; DRUG RESPONSE; EX VIVO STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; NORMAL HUMAN; PHARMACOGENOMICS; PHARMACOLOGY; PHARMACOMETABOLOMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PURINE METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; TREATMENT DURATION;

ADENOSINE KINASE; ADULT; ALLELES; ASPIRIN; DRUG RESISTANCE; FEMALE; HUMANS; MALE; METABOLOMICS; PLATELET AGGREGATION INHIBITORS; PURINES;

EID: 84884502711     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.119     Document Type: Article

References (34)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
2. Hovens, M.M., Snoep, J.D., Eikenboom, J.C., van der Bom, J.G., Mertens, B.J. & Huisman, M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 153, 175-181 (2007). (Pubitemid 46096871)
3. Wong, S., Appleberg, M., Ward, C.M. & Lewis, D.R. Aspirin resistance in cardiovascular disease: a review. Eur. J. Vasc. Endovasc. Surg. 27, 456-465 (2004). (Pubitemid 38529056)
4. Faraday, N. et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115, 2490-2496 (2007). (Pubitemid 46763222)
5. Goodman, T., Ferro, A. & Sharma, P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol. 66, 222-232 (2008).
6. Patrignani, P., Filabozzi, P. & Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366-1372 (1982). (Pubitemid 12081064)
7. Ohmori, T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 4, 1271-1278 (2006).
8. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet efect and clinical efcacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
9. Sabatine, M.S. et al. Metabolomic identifcation of novel biomarkers of myocardial ischemia. Circulation 112, 3868-3875 (2005). (Pubitemid 43739484)
10. Shah, S.H. et al. Association of a peripheral blood metabolic profle with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 3, 207-214 (2010).
11. Kaddurah-Daouk, R. et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6, e25482 (2011).
12. Kaddurah-Daouk, R. et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6, 191-201 (2010).
13. Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, e26 (2011).
14. Trupp, M. et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS ONE 7, e38386 (2012).
15. Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics- informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97-104 (2011).
16. Kaddurah-Daouk, R. & Krishnan, K.R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186 (2009).
17. Abo, R. et al. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet. Genomics 22, 247-253 (2012).
18. Mitchell, B.D. et al. The genetic response to short-term interventions afecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am. Heart J. 155, 823-828 (2008).
19. Shen, H. et al. Aspirin resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am. J. Cardiol. 104, 606-612 (2009).
20. Paul, S., Feoktistov, I., Hollister, A.S., Robertson, D. & Biaggioni, I. Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both efects are coupled to adenylate cyclase. Mol. Pharmacol. 37, 870-875 (1990). (Pubitemid 20219897)
21. Linden, M.D., Barnard, M.R., Frelinger, A.L., Michelson, A.D. & Przyklenk, K. Efect of adenosine A2 receptor stimulation on platelet activation-aggregation: diferences between canine and human models. Thromb. Res. 121, 689-698 (2008). (Pubitemid 351305291)
22. Hsiao, G. et al. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. Arterioscler. Thromb. Vasc. Biol. 25, 1998-2004 (2005). (Pubitemid 41243475)
23. Eltzschig, H.K. Adenosine: an old drug newly discovered. Anesthesiology 111, 904-915 (2009).
24. Macchi, L. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 107, 45-49 (2002).
25. Kemp-Harper, B. & Schmidt, H.H. cGMP in the vasculature. Handb. Exp. Pharmacol. 191, 447-467 (2009).
26. Jackson, E.K., Cheng, D., Jackson, T.C., Verrier, J.D. & Gillespie, D.G. Extracellular guanosine regulates extracellular adenosine levels. Am. J. Physiol., Cell Physiol. 304, C406-C421 (2013).
27. Levine, P.H., Sladdin, D.G. & Krinsky, N.I. Superoxide, xanthine oxidase and platelet reactions: further studies on mechanisms by which oxidants infuence platelets. Thromb. Haemost. 45, 290-293 (1981). (Pubitemid 11081039)
28. Patscheke, H., Paschen, W. & Wörner, P. Superoxide-independent platelet response to xanthine oxidase. Hoppe Seylers Z. Physiol. Chem. 359, 933-937 (1978). (Pubitemid 9060554)
29. Schlesinger, N. & Schumacher, H.R. Jr. Gout: can management be improved? Curr. Opin. Rheumatol. 13, 240-244 (2001). (Pubitemid 32430079)
30. Louthrenoo, W., Kasitanon, N., Wichainun, R. & Sukitawut, W. Efect of minidose aspirin on renal function and renal uric acid handling in healthy young adults. J. Clin. Rheumatol. 8, 299-304 (2002). (Pubitemid 35453596)
31. Spychala, J. et al. Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc. Natl. Acad. Sci. USA 93, 1232-1237 (1996). (Pubitemid 26052871)
32. Iyú, D., Glenn, J.R., White, A.E., Fox, S.C. & Heptinstall, S. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler. Thromb. Vasc. Biol. 31, 416-422 (2011).
33. Fiehn, O., Wohlgemuth, G. & Scholz, M. Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. Proc. Lect. Notes Bioinformatics 3615, 224-239 (2005). (Pubitemid 41420593)
34. Fiehn, O. et al. Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J. 53, 691-704 (2008). (Pubitemid 351224695)